Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 2013 International Congress of Parkinson’s Disease

  Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the
  2013 International Congress of Parkinson’s Disease and Movement Disorders

 Studies Further Define the Clinical Utility of AZILECT^® in the Treatment of
                           Parkinson’s Disease (PD)

2013 International Congress of Parkinson’s Disease and Movement Disorders

Business Wire

JERUSALEM -- June 14, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that a number
of abstracts will be presented during the 17^th Annual International Congress
of Parkinson’s Disease and Movement Disorders in Sydney, Australia, June
16-20, 2013, also known as the Movement Disorders Society (MDS). These
presentations affirm Teva’s ongoing commitment to Parkinson’s disease (PD)
research and underscore the potential of AZILECT^® as a treatment modality for
PD.

“The AZILECT^® abstract topics presented at MDS demonstrate our efforts to
further clarify the clinical utility of rasagiline ^ to prescribers and PD
patients across various stages of the disease,” said Michael Hayden, MD,
President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical
Industries Ltd. “We are committed to driving advances in research to help
address the treatment needs of those impacted by neurological conditions.”

Some of the presentations include:

  *[283] Efficacy and Tolerability of Rasagiline in Daily Clinical Use – A
    Post Marketing Observational Study in Patients with Parkinson’s Disease
    Focusing on Nonmotor Symptoms and QoL Data (Poster Session Topic: PD:
    Quality of Life/Caregiver Burden, Monday, June 17, 2013) Heinz Reichmann,
    Prof, Dr., Rainer Apfel, PhD, Sabrina Schroeder, PhD
  *[389] Efficacy of Rasagiline 1mg/day on Key Motor Symptoms of Early
    Parkinson Disease: Post-hoc Analysis from the Attenuation of Disease
    Progression with Azilect^® GIven Once-Daily (ADAGIO) Study (Poster Session
    Topic: PD: Clinical Trials, Tuesday, June 18, 2013) Eduardo Tolosa, MD, on
    behalf of the ADAGIO investigators (Selected for a guided poster tour:
    Thursday, June 20, 2013)
  *[446] A Placebo-Controlled, Randomized, Double-Blind Study to Assess the
    Safety and Clinical Benefit of Rasagiline as an Add-On to Dopamine Agonist
    Monotherapy in Early Parkinson’s Disease (PD): The ANDANTE Study (Poster
    Session Topic: PD: Clinical Trials, Tuesday, June 18, 2013) Robert A
    Hauser, MD, Dee Silver, MD, Azhar Choudhry, MD, Stuart Isaacson, MD
    (Selected for a guided poster tour: Thursday, June 20, 2013)

  *[387] A Randomized, Double Blind, Placebo-Controlled Study to Assess the
    Effect of Rasagiline on Mild Cognitive Impairment in Patients with
    Parkinson’s Disease: The MODERATO Study (Poster Session Topic: PD:
    Clinical Trials, Tuesday, June 18, 2013) D. Weintraub MD, R.A. Hauser MD,
    MBA, A. Choudhry MD, MBA

ABOUT AZILECT^® (UNITED STATES)

AZILECT^® (rasagiline tablets) is indicated for the treatment of the signs and
symptoms of Parkinson's disease (PD) both as initial therapy alone and to be
added to levodopa later in the disease.

Patients should not take AZILECT^® if they are taking meperidine, tramadol,
methadone, propoxyphene, dextromethorphan, St. John’s Wort, cyclobenzaprine,
or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious
reaction. Patients should inform their physician if they are taking, or
planning to take, any prescription or over-the-counter drugs, especially
antidepressants and ciprofloxacin. Patients with moderate to severe liver
disease should not take AZILECT^®. Patients should not exceed a dose of 1 mg
per day of AZILECT^® in order to prevent a possibly dangerous increase in
blood pressure.

Side effects seen with AZILECT^® alone are flu syndrome, joint pain,
depression, and indigestion; and when taken with levodopa are uncontrolled
movements (dyskinesia), accidental injury, weight loss, low blood pressure
when standing, vomiting, anorexia, joint pain, abdominal pain, nausea,
constipation, dry mouth, rash, abnormal dreams, and fall.

See additional important information at
http://www.azilect.com/Resources/PDFs/PrescribingInformation-pdf.aspx. For
hardcopy releases, please see enclosed full prescribing information.

AZILECT^® is currently available in more than 40 countries worldwide,
including the U.S., Canada, Israel, Mexico, and all EU countries. Teva has a
long-term agreement for the joint development and marketing of AZILECT^® in
Europe and some additional markets with H. Lundbeck A/S. In North America,
AZILECT^® is marketed by Teva's wholly-owned subsidiary, Teva Neuroscience,
Inc. (www.tevaneuro.com).

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management’s current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products, competition for our
innovative products, especially Copaxone® (including competition from
innovative orally-administered alternatives, as well as from potential
purported generic equivalents), competition for our generic products
(including from other pharmaceutical companies and as a result of increased
governmental pricing pressures), competition for our specialty pharmaceutical
businesses, our ability to achieve expected results through our innovative R&D
efforts, the effectiveness of our patents and other protections for innovative
products, decreasing opportunities to obtain U.S. market exclusivity for
significant new generic products, our ability to identify, consummate and
successfully integrate acquisitions, the effects of increased leverage as a
result of recent acquisitions, the extent to which any manufacturing or
quality control problems damage our reputation for high quality production and
require costly remediation, our potential exposure to product liability claims
to the extent not covered by insurance, increased government scrutiny in both
the U.S. and Europe of our agreements with brand companies, potential
liability for sales of generic products prior to a final resolution of
outstanding patent litigation. our exposure to currency fluctuations and
restrictions as well as credit risks, the effects of reforms in healthcare
regulation and pharmaceutical pricing and reimbursement, any failures to
comply with complex Medicare and Medicaid reporting and payment obligations,
governmental investigations into sales and marketing practices (particularly
for our specialty pharmaceutical products), uncertainties surrounding the
legislative and regulatory pathways for the registration and approval of
biotechnology-based products, adverse effects of political or economical
instability, corruption, major hostilities or acts of terrorism on our
significant worldwide operations, interruptions in our supply chain or
problems with our information technology systems that adversely affect our
complex manufacturing processes, any failure to retain key personnel or to
attract additional executive and managerial talent, the impact of continuing
consolidation of our distributors and customers, variations in patent laws
that may adversely affect our ability to manufacture our products in the most
efficient manner, potentially significant impairments of intangible assets and
goodwill, potential increases in tax liabilities, the termination or
expiration of governmental programs or tax benefits, environmental risks and
other factors that are discussed in our Annual Report on Form 20-F for the
year ended December 31, 2012 and in our other filings with the U.S. Securities
and Exchange Commission. Forward-looking statements speak only as of the date
on which they are made and the Company undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise.

Contact:

Teva Pharmaceutical Industries Ltd.
IR:
Kevin C. Mannix, 215-591-8912
United States
or
Ran Meir, 215-591-3033
United States
or
Tomer Amitai, 972-3-926-7656
Israel
or
PR:
Iris Beck Codner, 972-3-926-7687
Israel
or
Denise Bradley, 215-591-8974
United States